Literature DB >> 19153114

Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases.

A H Aljubran1, A Griffin, M Pintilie, M Blackstein.   

Abstract

BACKGROUND: Survival data are still limited and controversial about adult patients with osteosarcoma as older group of patients has mostly been excluded from the historical trials. PATIENTS AND METHODS: Patients with osteosarcoma, from 1986 to 2003, in a single center, were reviewed. Survival according to a cutoff age of 40 was studied. Patients with lung metastases were identified. Variables at first lung involvement including time to first lung metastases, multiplicity and size of the metastatic lesions and use of chemotherapy were all analyzed.
RESULTS: A total of 247 patients, with age range of 14-77 years, were reviewed. Five-year survival is 66% with no difference between patients <40 or >or=40 years. Eighty-five patients, with either synchronous or metachronous lung involvement, have 3-year postlung metastases survival (PLMS) of 30%. Forty-seven patients (55.3%) underwent lung resection with 3-year PLMS of 38% compared with 16% for nonoperated patients (P = 0.00023). Patients who developed lung metastases within a year and have fewer than four lung lesions have better PLMS (P < 0.0001 for both).
CONCLUSIONS: Older patients have identical survival to pediatric population and should have a similar management approach. Complete metastectomy is the key issue for prolonged survival. Time to lung metastases and number of lung lesions are the most important prognostic factors.

Entities:  

Mesh:

Year:  2009        PMID: 19153114     DOI: 10.1093/annonc/mdn731

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  70 in total

1.  Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.

Authors:  Jeremy J McGuire; Niveditha Nerlakanti; Chen Hao Lo; Marilena Tauro; Thomas J Utset-Ward; Damon R Reed; Conor C Lynch
Journal:  Int J Cancer       Date:  2020-06-29       Impact factor: 7.396

Review 2.  Moving beyond response criteria: new measures of success in the treatment of sarcomas.

Authors:  Andrew E Hendifar; Elke Ahlmann; Daniel C Allison; James Hu; Lawrence Menendez; Sant P Chawla
Journal:  Curr Treat Options Oncol       Date:  2012-09

3.  Association of MMP-2 expression and prognosis in osteosarcoma patients.

Authors:  Miao Zhang; Xuran Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 4.  Challenges and Opportunities for Childhood Cancer Drug Development.

Authors:  Peter J Houghton; Raushan T Kurmasheva
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

Review 5.  Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group.

Authors:  Ryan D Roberts; Michael M Lizardo; Damon R Reed; Pooja Hingorani; Jason Glover; Wendy Allen-Rhoades; Timothy Fan; Chand Khanna; E Alejandro Sweet-Cordero; Thomas Cash; Michael W Bishop; Meenakshi Hegde; Aparna R Sertil; Christian Koelsche; Lisa Mirabello; David Malkin; Poul H Sorensen; Paul S Meltzer; Katherine A Janeway; Richard Gorlick; Brian D Crompton
Journal:  Cancer       Date:  2019-07-29       Impact factor: 6.860

6.  IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis.

Authors:  Amy C Gross; Hakan Cam; Doris A Phelps; Amanda J Saraf; Hemant K Bid; Maren Cam; Cheryl A London; Sarah A Winget; Michael A Arnold; Laura Brandolini; Xiaokui Mo; John M Hinckley; Peter J Houghton; Ryan D Roberts
Journal:  JCI Insight       Date:  2018-08-23

7.  Highly metastatic K7M2 cell line: A novel murine model capable of in vivo imaging via luciferase vector transfection.

Authors:  Brian T Grisez; Justin J Ray; Phillip A Bostian; Justin E Markel; Brock A Lindsey
Journal:  J Orthop Res       Date:  2018-02-10       Impact factor: 3.494

8.  Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison.

Authors:  Tracy A Marko; Brandon J Diessner; Logan G Spector
Journal:  Pediatr Blood Cancer       Date:  2016-02-29       Impact factor: 3.167

9.  MicroRNA-433 regulates apoptosis by targeting PDCD4 in human osteosarcoma cells.

Authors:  Yinghua Sun; Fuchao Wang; Li Wang; Zhaode Jiao; Jun Fang; Jianmin Li
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

10.  Multimodality therapy for metastatic sarcomas confined to the lung.

Authors:  Russell P Gollard; J Francis Turner
Journal:  Oncol Lett       Date:  2012-07-24       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.